Long-term risk of serious infections and mortality among patients surviving drug use-associated infective endocarditis

Mary C Figgatt; David L Rosen; Vivian H Chu; Li-Tzy Wu; Asher J Schranz

doi:10.1093/cid/ciae214

Long-term risk of serious infections and mortality among patients surviving drug use-associated infective endocarditis

Clin Infect Dis. 2024 Apr 20:ciae214. doi: 10.1093/cid/ciae214. Online ahead of print.

Authors

Mary C Figgatt¹, David L Rosen², Vivian H Chu³, Li-Tzy Wu⁴, Asher J Schranz²

Affiliations

¹ Department of Medicine, University of Alabama, Birmingham, AL, USA.
² Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
³ Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
⁴ Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, and Department of Medicine, Duke University School of Medicine, Durham, NC, USA.

PMID: 38642403
DOI: 10.1093/cid/ciae214

Abstract

Among a statewide cohort of 1,874 patients surviving hospitalization for drug use-associated endocarditis during 2017-2020, the 3-year risk of death or future hospitalization was 38% (16% for death prior to later infection, 14% for recurrent endocarditis, 14% for soft-tissue, 9% for bacteremia, 5% for bone/joint, and 4% for spinal infections).

Keywords: bacterial infections; endocarditis; injection drug use; mortality.

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.